Oncobiologics, Inc. (NASDAQ:OTLK – Get Free Report) Director Faisal Ghiath Sukhtian acquired 95,398 shares of the business’s stock in a transaction dated Wednesday, July 29th. The shares were acquired at an average cost of $1.05 per share, with a total value of $100,167.90. Following the transaction, the director owned 220,972 shares in the company, valued at approximately $232,020.60. This trade represents a 75.97% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.
Oncobiologics Price Performance
NASDAQ:OTLK opened at $1.04 on Friday. Oncobiologics, Inc. has a one year low of $0.16 and a one year high of $3.39. The business has a fifty day moving average price of $1.24 and a 200-day moving average price of $0.67. The firm has a market capitalization of $154.53 million, a price-to-earnings ratio of -0.89 and a beta of 0.77.
Oncobiologics (NASDAQ:OTLK – Get Free Report) last released its earnings results on Friday, May 15th. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.04). The company had revenue of $0.13 million during the quarter, compared to the consensus estimate of $4.39 million. On average, equities research analysts expect that Oncobiologics, Inc. will post -0.49 earnings per share for the current fiscal year.
Trending Headlines about Oncobiologics
- Positive Sentiment: Director Faisal Ghiath Sukhtian purchased 95,398 shares at an average price of $1.05, investing approximately $100,168. The transaction increased his direct ownership by 75.97% to 220,972 shares, a potential signal of confidence in Oncobiologics’ outlook. SEC insider transaction filing
- Positive Sentiment: BTIG Research upgraded OTLK to “Buy” from “Neutral,” adding a more bullish analyst view. Separate coverage cited in the reports indicates BTIG assigned a substantially higher price target, although analyst opinions remain mixed. BTIG Research upgrade
- Positive Sentiment: HC Wainwright raised several 2027 EPS forecasts, including improving its full-year estimate to a loss of $0.03 from a loss of $0.21. The firm projects a return to profitability in 2028, with EPS of $0.09, followed by $0.15 in 2029 and $0.32 in 2030. These estimates support the longer-term bull case. HC Wainwright estimates
- Neutral Sentiment: HC Wainwright maintained a “Neutral” rating but lifted its price target to $1.60. Its quarterly forecasts generally improved for late 2026 and 2027, while the FY2026 EPS estimate was reduced slightly to a loss of $0.47 from $0.42, showing that near-term profitability remains uncertain.
- Negative Sentiment: Oncobiologics’ latest reported quarter showed a $0.16-per-share loss versus a $0.12 consensus loss, while revenue of $0.13 million fell far short of the $4.39 million estimate. The company is also expected to remain loss-making in the current fiscal year, increasing execution and financing risks.
Hedge Funds Weigh In On Oncobiologics
Several large investors have recently made changes to their positions in OTLK. Russell Investments Group Ltd. grew its position in shares of Oncobiologics by 865.2% during the second quarter. Russell Investments Group Ltd. now owns 24,477 shares of the company’s stock worth $39,000 after purchasing an additional 21,941 shares in the last quarter. AQR Capital Management LLC raised its stake in Oncobiologics by 42.7% during the 1st quarter. AQR Capital Management LLC now owns 84,671 shares of the company’s stock valued at $103,000 after purchasing an additional 25,351 shares during the period. Finally, Goldman Sachs Group Inc. lifted its holdings in Oncobiologics by 74.1% in the 1st quarter. Goldman Sachs Group Inc. now owns 103,524 shares of the company’s stock worth $126,000 after purchasing an additional 44,063 shares in the last quarter. 11.20% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
A number of research analysts recently issued reports on the company. Wall Street Zen downgraded Oncobiologics from a “hold” rating to a “sell” rating in a research note on Saturday, July 18th. Ascendiant Capital Markets raised their target price on shares of Oncobiologics from $6.00 to $10.00 and gave the stock a “buy” rating in a research note on Thursday, June 11th. Weiss Ratings downgraded shares of Oncobiologics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday. HC Wainwright lifted their price target on shares of Oncobiologics to $1.60 and gave the company a “neutral” rating in a report on Monday. Finally, BTIG Research upgraded shares of Oncobiologics from a “neutral” rating to a “buy” rating and set a $4.00 price target for the company in a research report on Monday. Two research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $4.65.
Check Out Our Latest Analysis on OTLK
Oncobiologics Company Profile
Oncobiologics, Inc is a clinical-stage biopharmaceutical company specializing in the development of biosimilar therapeutics for cancer and autoimmune diseases. Leveraging recombinant DNA technology and advanced formulation platforms, the company aims to create high-quality, cost-effective alternatives to originator biologic drugs. Oncobiologics’ research focus includes monoclonal antibodies and growth factors that support oncology treatment and immunomodulation.
Founded in 2005 and headquartered in Marlborough, Massachusetts, Oncobiologics maintains research facilities in the Greater Boston area and an integrated manufacturing site in Hyderabad, India, through its wholly owned subsidiary.
Featured Articles
- Five stocks we like better than Oncobiologics
- Microsoft Just Flipped the AI Spending Narrative Overnight
- Qualcomm’s Turnaround Is Working, So Why Is Wall Street Selling?
- Meta’s Earnings Show Why Wall Street Is Losing Patience With AI Spending
- Can Starbucks Keep This Turnaround Going? The Latest Results Say Yes
Receive News & Ratings for Oncobiologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncobiologics and related companies with MarketBeat.com's FREE daily email newsletter.
